Merrill: Confidence...
Health Care: Drugs
Dyax Corporation (DYAX: NASDAQ)
$2.52 0.00 | 0.00%
05/21/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -29.26M | -34.60M | -24.50M | -62.42M |
| Operating Gains/Losses | -110.00K | 0.00 | 43.00K | -42.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -1.34M | -810.00K | -2.61M | 2.01M |
| (Increase) Decrease in Inventories | -2.92M | -5.20M | -992.00K | -70.00K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -2.11M | 1.43M | -2.48M | -845.00K |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | -2.95M | -3.21M | -9.07M | -1.85M |
| Other Non-Cash Items | 6.28M | 6.02M | 5.06M | 6.34M |
| Net Cash From Continuing Operations | -28.48M | -36.45M | -34.13M | -54.23M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -28.48M | -36.45M | -34.13M | -54.23M |
| Sale of Property, Plant & Equipment | 200.00K | 0.00 | 38.00K | 74.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 23.00M | 35.50M | 47.00M | 39.00M |
| Purchases of Property, Plant & Equipment | -4.07M | -1.69M | -326.00K | -589.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | -3.02M | 0.00 | 0.00 |
| Other Cash from Investing Activities | 1.27M | -178.00K | 700.00K | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 14.34M | 30.61M | -35.41M | 6.99M |
| Issuance of Debt | 1.38M | 19.85M | 0.00 | 14.82M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 1.44M | 542.00K | 61.58M | 38.73M |
| Repayment of Long-Term Debt | -135.00K | 0.00 | -2.82M | -4.61M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | -1.68M | 0.00 | 0.00 |
| Net Cash From Financing Activities | 2.69M | 18.71M | 58.76M | 48.94M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 14.00K |
| Net Change in Cash & Cash Equivalents | -11.45M | 12.87M | -10.78M | 1.72M |
Portfolios with DYAX
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- UserSUPRATRADE-0303071618
- Userdulcinea
- ContributorOptions Action Portfolio Fe...
- UserLast Day of the JPMorgan He...
- UserBarron's Research Reports 7...
- UserPART 6 JPMorgan 26th Annual...
- Userpnp.v
- UserSpec #1
- Userjan's specs
Latest DYAX Headlines from TheStreet
- 5 Biotech Stocks Poised for Breakouts 07.27.12 | 01:07 pm
- Dyax Corporation CEO Discusses Q2 2012 Results - Earnings Call Transcript 07.19.12 | 08:07 pm
- Dyax's CEO Presents At Deutsche Bank AG Health Care Conference (Transcript) 05.07.12 | 03:05 pm
- Dyax Stock Gaps Down On Today's Open (DYAX) 07.19.11 | 09:07 am
- Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 03:10 am
- Dyax Corp. Q2 2010 Earnings Call Transcript 07.28.10 | 10:07 pm
- Merck Buys British Maker Of Biotech Medicines 12.17.09 | 12:12 pm
- Cubist Stops Enrollment In Anti-bleeding Studies 12.03.09 | 01:12 pm
- Delta, Walgreen, Diedrich Coffee Are Big Movers 12.02.09 | 04:12 pm
- Dyax Shares Rocket On FDA Clearance For Kalbitor 12.02.09 | 11:12 am
Press Releases for DYAX
- Dyax Corp. To Participate In The 25th Annual ROTH Conference - Business Wire 03.12.13 | 07:03 am
- Dyax Announces Management Change - Business Wire 03.08.13 | 08:03 am
- Dyax Presents DX-2930 Data At The 2013 American Academy Of Allergy, Asthma And Immunology Annual Meeting - Business Wire 02.25.13 | 07:02 am
- Dyax Corp. To Participate In Upcoming 2013 Healthcare Conferences - Business Wire 02.20.13 | 07:02 am
- Dyax Corp. Announces Fourth Quarter And Full Year 2012 Financial Results - Business Wire 02.13.13 | 04:02 pm
- Dyax Corp. And CVie Therapeutics Announce Partnership To Develop And Commercialize KALBITOR® (ecallantide) For Hereditary Angioedema (HAE) And Other Angioedema Indications In China, Hong Kong And Macau - Business Wire 02.07.13 | 07:02 am
- Dyax Corp. To Participate In The Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 07:02 am
- Dyax Corp. To Host Fourth Quarter And Year End 2012 Earnings Call And Webcast - Business Wire 02.05.13 | 07:02 am
- Dyax Corp. And Novellus Biopharma AG Announce Partnership To Develop And Commercialize KALBITOR® (ecallantide) For Hereditary Angioedema (HAE) And Other Angioedema Indications In Latin America - Business Wire 01.31.13 | 07:01 am
- Behind The Success - Research Report On Corcept Therapeutics Inc. And Dyax Corp. - PR Newswire 01.23.13 | 08:01 am
Partner Headlines for DYAX
- Microvision CRASHES 24% to Lead 3 NASDAQ Top Percentage Losers - Wall St. Cheat Sheet 06.18.12 | 09:06 am
- Barclays UPGRADES Dollar General to Overweight and 4 Stocks on Analyst Radars - Wall St. Cheat Sheet 06.15.12 | 04:06 am
- Morning Market Losers - Benzinga 07.19.11 | 09:07 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.13.11 | 09:07 am
- Low-Priced Biotech Stocks With Insider Buying - Seeking Alpha 03.18.11 | 06:03 pm
- Dyax Corp. Hits New 52-Week Low (DYAX) - Benzinga 01.04.11 | 09:01 am
- UPDATE 1-Dyax, Sigma-Tau agree to develop, market genetic drug - Reuters 06.21.10 | 08:06 am
- CORRECTED - CORRECTED-UPDATE 1-Dyax posts narrower-than-expected Q4 loss - Reuters 02.17.10 | 09:02 am
